Tango Therapeutics : Corporate Presentation

Targeting tumor suppressor loss

to unmask vulnerabilities in cancer

for the next generation of precision medicines

Corporate Overview

January 2023

| 1

Disclaimer and Safe Harbor Statement

Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future financial and operating performance, goals, expectations, beliefs, development plans, as well as development objectives for Tango's product pipeline (as individual therapies and combination therapies with other party's drugs). In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "path", "achievable", "milestones", "goal", "forecast", "estimate", "pot ential", "anticipate", "believe", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. For example, statements concerning the following include or constitute forward-looking statements: Company has a cash runway into 2025; Company has a state-of-the-art discovery platform supporting a sustainable pipeline of novel targets; the Company has three IND filings planned for 2023; the anticipated milestones for the Company's drug programs, including the timing for initial dose escalation data, timing of initial (and final) safety and efficacy or clinical activity data and results from clinical trial(s), the timing of first-in-human clinical trials, the timing of IND-enabling studies, the timing of IND filings, the timing of clinical trial initiation and the timing of development candidate declaration; Tango has a sustainable pipeline of novel precision oncology targets; Tango's discovery platform and its increased probability of meaningful clinical results; the Company's lead program is a potentially first-in-class PRMT5 inhibitor that is synthetic lethal with MTAP deletion; there is a clear path to clinical POC for PRMT5 inhibitor in MTAP-null solid tumors with multiple histologies; potential for histology-agnostic registration for PRMT5 inhibitor with broad based activity across tumor types; TNG908 is a potentially first-in-class PRMT5 inhibitor that is synthetic lethal with MTAP deletion; the Company will be pursuing novel combination therapies with inhibitors that have a complementary mechanism of action; the Company is actively enrolling patients in the TNG908 clinical trial; TNG908 expansion cohorts provide optionality for multiple registration strategies; TNG908 expected to be brain penetrant in clinical study; TNG462 is potential best-in-class PRMT5 inhibitor (and has potential for broader and deeper clinical activity and is expected to have an increased therapeutic index and efficacy); the development plans for the PRMT5 franchise (including future clinical trials); future clinical trial designs; TNG260 future clinical trial implementation; the significant patient opportunities for the Company's pipeline therapies; synergy of USP1 in both PARP-sensitive and -resistance models suggests potential to meaningfully expand patient benefit from PARP inhibitors; Tango has sufficient cash balance to fund operations into 2025 (and is sufficient to achieve multiple projected key milestones); the Company's key milestones for 2023 and 2024; treatment of KRAS G12Cmut/ MTAP null lung adenocarcinoma with TNG908 and a KRASG12C inhibitor may be of clinical benefit; the anticipated benefits of synthetic lethal drugs; planned expansion cohort of the TNG908 phase 1/2 clinical trial for glioblastomas; and the anticipated benefits of future product candidates including those identified in the future through the Tango discovery platform. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. Drug development, clinical trials and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Tango has a limited operating history and has not generated any revenue to date from drug sales, and may never become profitable (and may utilize cash resources more quickly than anticipated); Tango has limited experience with conducting clinical trials (and will rely on a third party to operate the clinical trial for TNG908) and may not be able to commence any clinical trial, enroll and dose patients when expected and may not generate results in the anticipated timeframe (or at all); IND filings may not be made in the time expected or the FDA (or similar regulatory agencies) may not accept such IND applications (or may require that significant changes be made to the IND application that could significantly delay or prevent the commencement of clinical trials); the benefits of Tango pipeline products (stand-alone and as potential combination therapies) that are seen in pre-clinical experiments may not be present in clinical trials or in use commercially or may not be safe and/or effective in humans (and Tango or a third-party may not be able to obtain approval or commercial sales of any stand- alone or combination therapies); Tango has incurred significant operating losses and anticipates continued losses for the foreseeable future; Tango will need to raise capital in the future and if it is unable to raise capital when needed or on attractive terms, the Company would be forced to delay, scale back or discontinue some development programs or future commercialization efforts; Tango may be unable to advance the preclinical development programs into and through the clinic for safety or efficacy reasons or experience significant delays in doing so as a result of factors beyond Tango's control; Tango's approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; Tango may not identify or discover development candidates (including next generation products) or may expend a portion of its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; delays or difficulties in the initiation, enrollment or dosing of patients in clinical trials could delay or prevent receipt of regulatory approvals; our products candidates may cause adverse or other undesirable side effects that could, among other things, delay or prevent regulatory approval; our dependence on third parties for conducting clinical trials and producing drug product; our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad; and delays and other impacts on product development and clinical trials from the COVID-19 pandemic. Additional information concerning risks, uncertainties and assumptions can be found in Tango's filings with the SEC, including the risk factors referenced in Tango's Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.'

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Tango's own internal estimates and research. In addition, the market data included in this presentation involve a number of

assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while Tango believes its internal research is reliable, such research has not been verified by any independent source.

| 2

COMPANY OVERVIEW

| 3

Tango summary

Clinical-stage precision oncology company leveraging synthetic lethality

State-of-the-art discovery platform supporting a sustainable pipeline of novel targets

First clinical trial ongoing and three IND filings planned for 2023

• • Initial dose escalation data for TNG908 1H 2023 - a novel synthetic lethal PRMT5 inhibitor for MTAP-deleted cancers
  • IND cleared for TNG462 January 2023 - a next generation synthetic lethal PRMT5 inhibitor
  • IND filing for TNG260 1H 2023 - a novel CoREST inhibitor targeting immune evasion caused by STK11 mutations
• • IND filing for TNG348 mid-2023 - a novel USP1 inhibitor for BRCA1/2 mutant cancers

Cash runway into 2025

| 4

A strong strategic partnership with Gilead

SCOPE

RESEARCH AND

DEVLOPMENT

RIGHTS

SHARED

ECONOMICS

TERMS

• 15 validated immune evasion targets
• Two targets licensed, two optioned to date
• Target discovery and validation at Tango with option to extend to clinical POC
• Gilead will lead post-POC development and commercialization
• Full rights retained to TNG260 and all cell autonomous targets not associated with immune evasion
• Option to co-develop/co-promote up to five programs
• 50/50 US profit/loss sharing on co-developed programs
• Low double-digit royalties on all other programs
• $175 million upfront
• $20 million equity
• Up to $110M to clinical POC, $410M per program and up to $6 billion in milestones

| 5